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Abstract
As genome or exome sequencing (hereafter genome-scale sequencing) becomes more integrated 
into standard care, carrier testing is an important possible application. Carrier testing using 
genome-scale sequencing can identify a large number of conditions, but choosing which 
conditions/genes to evaluate as well as which results to disclose can be complicated. Carrier 
testing generally occurs in the context of reproductive decision-making and involves patient values 
in a way that other types of genetic testing may not. The Kaiser Permanente Clinical Sequencing 
Exploratory Research program is conducting a randomized clinical trial of preconception carrier 
testing that allows participants to select their preferences for results from among broad descriptive 
categories rather than selecting individual conditions. This paper describes 1) the criteria 
developed by the research team, the return of results committee (RORC), and stakeholders for 
defining the categories; 2) the process of refining the categories based on input from patient focus 
groups and validation through a patient survey; and, 3) how the RORC then assigned specific 
gene-condition pairs to taxonomy categories being piloted in the trial. The development of four 
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categories (serious, moderate/mild, unpredictable, late onset) for sharing results allows patients to 
select results based on their values without separately deciding their interest in knowing their 
carrier status for hundreds of conditions. A fifth category, lifespan limiting, was always shared. 
The lessons learned may be applicable in other results disclosure situations, such as incidental 
findings.
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Carrier testing; genome sequencing; return of results
INTRODUCTION
Genome-scale sequencing is currently offered primarily in research contexts and its clinical 
use is focused on molecular diagnosis for unresolved clinical questions. This approach can 
also be used for carrier testing for autosomal recessive or X-linked conditions [Green et al. 
2013], but there is limited experience in this context. Although carrier testing for specific 
diseases, such as cystic fibrosis (CF) and β-thalassemia [Mennuti 2008], is well-established 
in practice, there are scant data about what carrier testing results patients would find 
valuable if given the choice of genome-scale sequencing, which can assess hundreds of 
autosomal recessive or X-linked conditions. Data are also lacking on how to disclose the 
results of genome-scale sequencing in ways that are meaningful to clinicians and respectful 
of patient preferences.
Population-specific carrier panel testing has a well-established history, and these panels test 
for conditions whose outcomes range widely, from expected death in childhood to those with 
milder manifestations. For example, test panels developed for the Ashkenazi population 
typically included Tay-Sachs disease, CF, Gaucher disease and others [Klugman and Gross 
2010]. Tay-Sachs disease is usually fatal by 6 years of age [2009]; CF causes chronic 
respiratory and digestive problems, but people with CF have an increasingly improved life 
expectancy because of evolving medical interventions [2011]. Gaucher disease has such 
phenotypic variability that it may result in childhood death (a rare subtype) or normal 
lifespan with no recognition of the condition [2009]. Initially, panels comprising 3–12 tests 
were offered as “all or nothing,” and laboratories often charged more to test for less than the 
full panel [Leib et al. 2005]. This restricted patient choice for obtaining only the results of 
interest to them, as customization was, in effect, a billable service.
Some commercial laboratories now offer carrier panels comprising more than 100 
conditions. The challenge with this approach remains the same: certain patients may be 
interested in testing for some, but not all, conditions. Furthermore, it is difficult to provide 
informed consent for every condition without an extended counseling visit [Elias and Annas 
1994].
As part of a randomized clinical trial to offer genome-scale sequencing for preconception 
carrier testing, our research team created a taxonomy of genetic conditions using categories 
to guide decisions rather than asking people to decide disease-by-disease. The intent was to 
learn how to leverage genome-scale sequencing effectively while supporting individual 
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preferences. Sorting conditions into broader categories can potentially reduce the burden on 
patients and providers by allowing patients to select preferences from among these 
categories in keeping with patient autonomy in a reproductive, values-based context.
This paper describes the evolution of the taxonomy of condition categories, which included 
incremental iterations based on conceptual analyses by an interdisciplinary team concerning 
what characteristics are likely to matter most to patients for reproductive decision-making, 
augmented by empirical data from patients. Delineating the complex process of developing 
this taxonomy of condition categories is important so that others might consider the 
complexities involved in sharing category-based results—many of which touch upon patient 
values—in other contexts.. Creating this taxonomy began with an awareness of the ethical 
complexity of reproductive decision making. In addition to the personal values that may 
guide decisions, there are also political sensitivities surrounding the issues of abortion as 
well as the use of public funding for special education options to support children with 
health conditions or disabilities [Pergament 2013].
Stakeholders, including patients, clinicians, policymakers, and advocacy groups representing 
populations with diseases or disabilities have an interest in which conditions are included in 
testing choices and how those conditions are described. Three issues raise ethical concerns 
in the context of reproductive genetic testing. First are questions about which diseases to 
include or exclude from testing, such as adult onset diseases and diseases with unpredictable 
impact. The second is how to describe those diseases that are included, such as what 
constitutes a “severe” disease. Third are concerns about which variants to disclose: 
commitments to open disclosure must be balanced with constraining information to 
interpretable findings to limit the impact of uncertain findings on reproductive decision 
making. In addition, all three of these areas of concern include issues surrounding the 
potential impact on those tested and on populations with genetically linked diseases or 
disabilities.
Conditions with unpredictable impact or impact in adulthood have not been traditionally 
included in most carrier testing programs. In considering adult onset conditions, respecting 
the child’s “right to an open future,” particularly as children can be tested as adults when 
they choose for themselves, must be weighed against the potential benefit to children 
because parents can prepare children for disease or disability later in life [de Jong et al. 
2011]. For conditions that are much more unpredictable (i.e., Gaucher disease), parents will 
need to balance the value of knowing about such a condition in their child with the potential 
for unnecessary anxiety and stigmatization.
Determining what conditions are described as “serious” is complicated by the subjectivity of 
the label and the potentially wide-ranging societal implications of that label. Those who 
advocate for the rights of disabled populations are concerned that the inclusion on carrier 
panels of disabilities that are associated with limited medical implications (e.g., 
nonsyndromic deafness, achondroplasia), sends messages to disabled populations and to 
parents that they are of lesser societal value with a disproportionate focus on the disability 
rather than on the person [Boardman 2014; McGuinness 2013]. Because this devaluing 
occurs in the context of societies that already have histories of discriminating against those 
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with disabilities [Munger et al. 2007; Parens and Asch 2003], undermining the value of these 
populations could be an unintended and negative consequence of genetic testing to inform 
reproductive planning.
When considering what variants to include, some would argue that more information can 
only promote parental choice, and this has been framed as “knowledge is power” by its 
advocates. But others point to the challenge of including variants of unknown significance 
and misinterpretations that may increase anxiety or lead to decisions to terminate 
pregnancies that are later regretted as more information and potential interventions become 
available. In light of these complexities and in support of informed patient decision making, 
determining the most appropriate categories to share in the context of reproductive planning 
is crucial. Broad categories that focus on the characteristics of most concern to potential 
parents can allow genetic counselors to fulfill what has been described as a “dual role”—
serving as disability advocates while also supporting reproductive choice based on parental 
needs [Peterson 2012].
Our team grappled with these issues in developing a clinical trial that attempted to promote 
decision making that would be consistent with patient values and mindful of the challenges 
of population carrier testing [Press et al. 2011].
METHODS
The development of the taxonomy had two main phases (see Figure 1). During the first 
phase (Tables I–IV), the initial taxonomy from the project proposal was revised to reflect 
important distinctions between categories based upon potential clinical relevance and patient 
preferences. Revisions during this phase relied on a consensus process involving the entire 
study team, including a panel of experts called the Return of Results Committee (RORC). 
The RORC comprises a panel of experts in clinical and laboratory genetics, pediatrics, and 
obstetrics whose charge is to provide clinical and scientific guidance about result 
interpretations, guide decisions about whether to share results, and if results are to be shared, 
advise on what category results should be placed in. The second phase of the taxonomy 
development involved refinement and validation using patient input (Table V) and 
assignment of conditions to categories by the RORC (Table VI).
RESULTS
PHASE ONE – INITIAL TAXONOMY REVISIONS
Initial taxonomy—The research team started with a four-part taxonomy (see Table I) that 
drew upon the team’s expertise and that was also informed by the genetic testing literature. 
Decisions made at this early stage included choosing the category name for conditions that 
lead to early death; although “childhood lethal” was considered first, the research team 
eventually chose “lifespan limiting” as a more emotionally neutral description. Three 
categories focused on the severity of the conditions as the main delimiting factor, and an 
additional fourth category (“quality of life”) served as a catch-all for those conditions that 
were not considered medically severe but did impact life experience significantly. The 
proposed strategy was that study participants would always be given results for the most 
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serious category, lifespan limiting, but could choose what to receive from the remaining 
three categories. The main challenge at this preliminary stage was creating categories that 
grouped conditions in a way that was both clinically accurate and meaningful to patients.
Distinguishing between impairments and medically involved conditions—Once 
the project started, the research team, comprising pediatricians, genetic counselors, medical 
geneticists, health services researchers, a bioethicist, a psychologist, and an anthropologist, 
created a second version of the taxonomy to provide more clarity in the descriptions for each 
category (see Table II). The category “treatable” was now labeled as “medically involved” to 
convey that the child would have recurrent interaction with the health care system and 
require regular attention to medical issues, with treatments that might range from special 
diets to occasional hospitalizations. “Quality of life” was reframed as “impairment,” to 
acknowledge that all conditions, not only less severe ones, can affect quality of life and that 
some conditions resulted in impairments without necessarily impacting quality of life 
adversely. In addition, some elements in the category “late onset or variable expression” 
were moved to a new standalone category, “variable impacts,” to recognize that variability in 
disease expression and outcomes represented a distinction worth considering apart from the 
other categories. Appreciating some variability for the first three condition categories, the 
research team further illustrated those categories by including descriptions of the experience 
of most children.
Distinguishing between cognitive and physical impairments and including 
variability for all categories—After further discussion, the research team determined 
that two categories needed additional clarification. The research team decided that for 
impairments, physical and cognitive should be distinguished from each other, while for 
variability, age of onset and variability of impact should also be distinguished (see Table III). 
The categories were all now deliberately ranked in descending order of severity, and in this 
new schema, intellectual impairments were defined as those that precluded independent 
adult functioning. Based on this definition of intellectual impairment, “medically involved” 
was considered “less severe” because, although medically involved included conditions that 
would require regular medical interactions, intellectual impairments were seen as creating 
lifelong dependency. The key difference that the research group focused on was whether a 
child would need parental or external care for his entire life or would be able to transition to 
an independent adulthood.
At this point in the taxonomy creation, variability became a modifier in terms of impact and 
age for each condition rather than its own category. However, by distinguishing variability 
for each condition category, the taxonomy now included 12 categories. The research team 
became concerned that this level of granularity would create more confusion than clarity, not 
least because many condition phenotypes involve more than one category, making it difficult 
to know where to place those conditions.
Distinguishing severity of impacts—The RORC reviewed the new categories and 
advised further refinements. Rather than emphasize variability, the committee advised that 
each category should instead focus on distinguishing between severe and mild (see Table 
IV). The committee further recommended that the “shortened lifespan” category should have 
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three distinctions: children who do not live past 5 years of age, children who do not live to 
18 years, and adults who do not live past 40. Although some distinctions were removed 
(variability of impact and age of onset for each condition category), the life expectancy and 
mild or severe specifications added further complexities. In addition, variable impact was no 
longer a focus for each category, as the RORC pointed out that genetic counselors routinely 
manage discussions of variability as part of the counseling process. Instead, variable age of 
onset transitioned into a separate category: “adult onset conditions.”
PHASE TWO – TAXONOMY REFINEMENT, VALIDATION, AND TESTING
Refinement reflecting patient input and emphasizing severity and 
unpredictability—The research team held three focus groups with 15 women and one 
man (n=16) who had recently received carrier testing as part of their usual medical care to 
review the taxonomy categories [Schneider et al.]. All participants were members of Kaiser 
Permanente Northwest residing in Oregon or Southwest Washington and were asked for 
their opinions about the second and third versions of the taxonomy (Tables II and III). The 
focus groups confirmed that severity and age of onset were key distinguishing factors and 
that “shortened lifespan” was important as a discrete category. Variability was regarded as 
less critical, and participants indicated that the research team should consider the most 
severe version of the condition that is routinely seen to determine the criteria for 
categorization. They reinforced the view of the RORC that variability could be addressed in 
genetic counseling. The focus groups also suggested having results expressed in a 
straightforward manner, in hopeful terms that were readily understandable but not 
deceptively optimistic. They wanted to better understand potential impacts on family life, a 
consideration that was not originally prioritized in the taxonomy.
The taxonomy was revised based on this input and the advice of the RORC (see Table V). 
The resulting taxonomy emphasized “serious conditions” as a separate category. This was 
considered a broad default category. Most conditions would fall within this new category 
unless they were associated with early death (“conditions with significantly shortened 
lifespans”) or very mild. “Conditions with unpredictable outcomes” included conditions that 
could manifest in a broad spectrum from mild (or unaffected) to severe, and where it would 
not be possible to predict outcome based on genotype. The research team retained late onset 
as a category because focus group participants were divided about whether they would want 
to learn about these conditions in preconception testing, indicating that it could be useful in 
facilitating decisions about testing.
At this stage, the research team also added examples to each category to highlight key 
characteristics and demonstrate how the categories would be applied. In both categories and 
their examples, the distinction between intellectual and physical impairments was 
abandoned because the focus had shifted to severity of condition. The research team 
modified the definitions and explanations in the taxonomy to emphasize that all of the 
genetic conditions would have an impact on both child and family life, but that with family, 
medical, and social support, even children with serious conditions would have meaningful 
and valuable lives. This is the version of the taxonomy that the research team is currently 
using with participants in the ongoing clinical trial.
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Validation using a survey about perceptions of genetic conditions—
Concomitant with the focus groups, the research team deployed a survey to validate the 
taxonomy categories among a broader participant base compared with the limited number of 
subjects in the focus groups. Through a process of expert consensus, the research team 
identified 20 genetic conditions that exemplified characteristics likely to drive prospective 
parents’ decisions about carrier testing. Five versions of the survey that each included 4 of 
the 20 conditions were administered to 193 people who had received carrier testing in the 
past. They reviewed the condition descriptions and rated them on a variety of attributes, such 
as how respondents would perceive the condition (severe, variable, controllable, visible, 
etc.). Survey participants independently perceived attributes that were consistent with the 
key characteristics of each category developed by the research team. More detailed results of 
this survey are reported in this same issue of this journal [Leo et al.].
Assignment of conditions to each category—The RORC developed a list of gene/
condition pairs from sources including existing commercial panels, published literature, and 
clinical experience. The process of choosing where to place each gene/condition pair in the 
taxonomy categories was complicated. Considerations included determining how much and 
what data was needed to be able to place a gene/condition pair into a particular category; 
how to handle conditions associated with multiple genes; how to handle variants in the same 
gene that may cause more or less severe phenotypes; and how to handle gene-condition pairs 
that could fit into multiple categories. The RORC considered these issues and advised that 
categories needed more specific definitions for the purpose of assignments. Furthermore, the 
RORC determined that a single category needed to be chosen in cases where category 
boundaries were crossed (e.g., allelic heterogeneity, genes with multiple phenotypic 
outcomes). Because many conditions fit into multiple categories, “serious” became the 
default assignment. This included X-linked conditions, which would assume the most severe 
outcome (male category).
However, gene-condition pairs that fit in multiple categories were flagged for variant review 
by the RORC. If a known milder variant was found during testing, and the participant did 
not select the mild category, results concerning that variant would not be disclosed. If a 
condition appeared lifespan limiting, but there were fewer than 3 cases, it was placed into 
the default serious category; lifespan limiting was defined as at least 50% of affected fetuses 
or children dying before the age of 10 years. The research team only required that the gene-
condition pair be found in one person per family in order to categorize it.
The RORC used the condition thresholds described in the taxonomy in order to assign gene-
condition pairs (see Table VI). For these assignments, each condition is placed in only one 
category. The exception is when there are several different forms of the same condition that 
can be distinguished from each other based on genotype (i.e., different genes or different 
mutations in the same gene). In this case, each distinguishable form of the condition can be 
placed in a separate category. For instance, the severe, infantile form of Gaucher disease 
would be in the ‘lifespan limiting’ category, whereas the mild, adult onset form of Gaucher 
would be in the ‘late onset’ category. Although specific percentages are listed in Table VI, 
these are meant as clarifiers to the descriptive words rather than thresholds. In many 
instances, the chances of certain events happening will not be precisely reported. Thus, 
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descriptions like rarely, mostly, often, etc., will need to be interpreted based on the 
clarifications defined in Table VI. The process of assigning conditions to these categories is 
ongoing, and the results will be reported in a subsequent paper.
DISCUSSION
Use of categories to specify results disclosure represents an intentional approach to genome-
scale sequencing that supports individual decisions without asking patients to accomplish 
the impractical task of deliberatively deciding about each condition individually. This 
approach seeks to use genome-scale sequencing with nuance rather than using the 
technology to disclose everything simply because it can be done. One benefit of choosing 
from categories of conditions rather than specific conditions is that generic categorical 
information (e.g., severity of impact, age at onset) can be more meaningfully described and 
considered, because the broad categories can be based on features of the conditions with 
which most people can identify. Specific diseases may have technical and confusing names 
and features, while the categories can be described in non-specialist, accessible language. As 
the number of conditions for which testing can be performed increases, the challenge 
involved in asking patients to make decisions about individual conditions becomes 
impractical, and the ability to ensure adequate understanding for consent becomes more 
challenging.
Our proposed approach has an element of arbitrariness that the research team explicitly 
acknowledges. Although the taxonomy categories were devised and refined based on 
extensive feedback, the lines drawn between categories are still subjective boundaries. As 
the process of taxonomy creation illustrates, categories shifted from one iteration to the next, 
sometimes adding new distinctions and sometimes returning to prior ones. The detailed 
descriptions and examples of conditions for each category can help others operationalize the 
taxonomy. Our research team expects that use of the taxonomy in our trial and formally 
evaluating its utility will help refine categorizations further in an ongoing, iterative process.
Determining which conditions are significant enough that patients should be offered testing 
to inform reproductive planning can be challenging and is ethically charged. We addressed 
this by having a diverse “serious” category (that includes cystic fibrosis and 
phenylkentonuria) as a way to accommodate this tension. The primary determinant became 
not a question of disease “severity,” but rather whether or not a condition would have a 
significant impact on a person’s life, particularly in terms of the need for medical treatment 
and management. In this way, the truly severe conditions (life span limiting) were 
constrained to conditions that caused death in childhood. Our approach to the ethical issues 
related to the inclusion of adult onset, unpredictable and mild conditions was to highlight 
these categories for patients, so they can decide if the distinctions are meaningful to them. 
As genome-scale sequencing moves closer to becoming a part of usual care [Manolio et al. 
2013], it is increasingly important to consider how to accommodate patient preferences for 
carrier testing and support informed decision-making.
Stakeholder input was critical in creating the optimal taxonomy categories and content. 
Patients’ suggestions about the taxonomy highlight the fact that test results affect people’s 
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lives, and test results about genetic conditions may provide valuable information that can 
shape both reproductive and life decisions with long-term and wide-ranging consequences 
[Press et al. 2011]. Therefore, great care should be taken to identify and accommodate 
patient information needs through careful presentation of the choices among results available 
to patients. The RORC, which used the categories for results assignment, required a greater 
level of specificity than that used to explain the categories to patients.
One limitation in the process of taxonomy creation and refinement that should be noted 
concerns timing. Because the timeline for our project deliverables was compressed, the 
survey and focus groups happened at the same time, rather than sequentially. The survey was 
implemented using an earlier version of the taxonomy, which was subsequently refined with 
input from the focus groups. It would have been optimal to refine the taxonomy with the 
focus groups first and then use the survey to confirm the focus group findings. This would 
have provided broader validation of the taxonomy categories as well as identified areas 
needing further refinement. Doing things in this order would have ensured that the focus 
groups would not identify elements that could have radically altered the taxonomy and, 
hence, the survey content used to provide a more direct validation of the RORC final 
taxonomy.
Conclusions and future directions
The iterative approaches to the development of the taxonomy allowed the research team to 
consider different ways of arranging information to add value and meaning to the categories 
described. Categories were then refined and confirmed through qualitative focus groups and 
a survey whose findings provided empirical support that validated the categories. In the 
current taxonomy, which is now being tested, issues related to the severity and 
unpredictability of conditions were prioritized. This process shows how categories expanded 
and contracted as the research team struggled to create categories that were meaningful from 
clinician, laboratory, and patient viewpoints. Future research might explore whether giving 
people control of the results returned is helpful and, if so, whether the categories themselves 
contribute to usefulness in the context of preconception carrier testing. In addition, other 
clinical studies could investigate the process of taxonomy creation to determine if the main 
features of the categories derived are useful to other teams using genome-scale sequencing 
in different clinical contexts. Finally, other studies are needed to test alternative approaches 
and evaluate our taxonomy in other patient populations with higher ethnic and racial 
diversity than the Pacific Northwest.
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Figure 1. 
The process of taxonomy development
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Table I
Initial proposed taxonomy
Categories of genetic conditions
Lifespan limiting
Severe conditions that lead to death in childhood. Also includes conditions where the fetal genotype might adversely impact the
pregnancy.
Treatable
Conditions that are severe if untreated but have a known treatment, usually diet. Many are part of newborn screening.
Late onset or variable expression
Conditions that do not greatly limit lifespan, or conditions that might be severe, at least for some people, but might also be near-
normal in phenotype.
Quality of life
Conditions that do not significantly limit lifespan, but do impact quality of life, such as hearing loss, vision loss, developmental
delay, loss of gross motor control, etc.
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Table II
Distinguishing between impairments and medically involved conditions
Categories of genetic conditions
Shortened lifespan
Most children have a shortened lifespan and few live into adulthood, even with medical interventions.
Medically involved
Most children take daily medications or use special diets and require regular medical care, and some may need occasional
hospitalizations. Some of these conditions are detected by newborn screening.
Impairments
Most children will have impairments that will affect their lives, such as reduced hearing, vision, mobility, or intellectual
functioning.
Variable impacts
Some children may have shortened lifespans, be medically involved, or have impairments, but others will have no problems
during childhood.
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Table III
Distinguishing between cognitive and physical impairments and including variability for all categories
Categories of genetic conditions Variable impact
(fewer than half of
children will be
affected)
Variable age
(fewer than half
so affected as
children)
Shortened lifespan
Most children have a shortened lifespan and few live into adulthood, even
with medical interventions.
Intellectual impairments
Most children will have intellectual impairments that will result in long-term
dependency on others for care.
Medically involved
Most children take daily medications or use special diets, and require regular
medical care, and some may need occasional hospitalizations. Some of these
conditions are detected by newborn screening.
Physical impairments
Most children will have impairments that will affect their lives significantly,
such as hearing, vision, or mobility impairments.
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Table IV
Distinguishing severity of impacts
Categories of genetic conditions
Shortened lifespan
Many children do not live past 5 years of age, even with medical interventions
Many children do not live past 18 years of age, even with medical interventions
Many adults do not live past 40 years of age, even with medical interventions
Serious Mild
Intellectual impairments Many children will have long-term
dependency on others for care
Many children will not be high achievers in
school but can function independently as
adults
Medically involved Many children take daily medications or use
special diets, and typically see a doctor four
or more times a year and may need
occasional hospitalizations
Many children will need to follow a special
diet or take daily medications, and typically
need to see a doctor fewer than four times a
year
Physical impairments Many children will have impairments that
will affect their lives daily, such as serious
hearing, vision, or mobility problems
Many children will be clumsy and not excel in
sports or have reduced vision or hearing
Adult onset conditions Most people do not develop symptoms until
adulthood, but these symptoms typically
include serious intellectual or physical
impairments, or are very medically involved
Most people do not develop symptoms until
adulthood, and these symptoms typically
include mild intellectual or physical
impairment or are mildly medically involved
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Table V
Taxonomy used with participants (reflecting patient input and emphasizing severity and unpredictability)
Categories of Genetic Conditions Do you wish to
receive these
results?
Conditions with significantly shortened lifespan
Everyone will receiveMost children do not live past early childhood, even with medical interventions
Tay-Sachs results in the gradual loss of movement and mental function. Infants develop increasing
seizures, vision and hearing loss, and severe mental disability. Death usually occurs by age 4.
Serious conditions
□ Yes
□ No
Most children will have medical problems that require regular medical visits, daily
medications, carefully monitored diets, or surgeries; or will have serious problems with
learning, vision, hearing or mobility. Children may have shortened life spans into early
adulthood.
Duchenne Muscular Dystrophy causes gradual loss of muscle function, beginning at five years of
age. Children benefit from wheel chairs, and medications can support breathing and cardiac
function, but most people do not live past their 20s.
People with Phenylketonuria (PKU) follow a very restrictive low protein diet for life to avoid
problems with learning and behavior.
Usher Syndromecauses severe hearing loss from birth and vision loss later in childhood. In
adolescence, people develop night blindness and a gradual loss of peripheral (side) vision.
Batten Disease causes gradual loss of brain functions, beginning between 5–10 years of age with
gradually worsening seizures, visual problems, and learning. Most children do not live past their
teens or 20s.
Cystic Fibrosis affects the lungs and digestive system. People with CF require frequent doctor visits
and typically take many medications. The average life expectancy is 35 years, but this continues to
improve with new treatments.
Mild conditions
□ Yes
□ No
Most children will have medical problems that require occasional extra medical visits,
occasional medications, a slightly modified diet, or surgery; or will have mild problems with
learning, vision, hearing, or mobility.
People with Ataxia with Vitamin E Deficiency develop clumsy hand movement, and reduced
awareness of body positioning as older children. Later symptoms may include difficulty speaking
and loss of some vision. These problems can be reduced with taking Vitamin E daily.
Ichthyosis is characterized by scaling of the skin, particularly on the neck, trunk and lower
extremities. Typically this scaling improves with age and during the summer months. This condition
typically does not affect intelligence or behavior.
Conditions with unpredictable outcomes
□ Yes
□ No
It is difficult to predict the outcome for many children. Some children will have more serious
versions but others will have more mild versions or no problems at all.
Gaucher Disease Type 1 causes degenerative bone disease and low blood counts. While some
people develop symptoms in childhood others have few symptoms even as adults. For those who do
have these symptoms, treatments can reduce symptoms.
Limb Girdle Muscular Dystrophy cause muscle weakness that affects the ability to walk and run.
Some people are affected as children but others are not affected until adulthood. Some people lose
the ability to walk within 10 years, but other people have less serious problems.
Conditions that begin as adults
□ Yes
□ No
Few have any symptoms as children, but medical, behavioral, vision, or hearing problems may
begin as adults.
Hemochromatosis causes liver, heart, and pancreas problems. The first symptoms typically begin
between the ages of 30 and 50, and can be treated relatively effectively, if they even develop at all.
Alpha-1 Antitrypsin Deficiency causes emphysema (progressive breathing difficulty and a frequent
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Categories of Genetic Conditions Do you wish to
receive these
results?
cough) with symptoms typically developing after age 60 in non-smokers and after age 40 in
smokers.
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Table VI
Definitions used by RORC for category assignment
Categories of genetic conditions
Lifespan limiting (childhood)
Greater than 50% die before age 10. Some people may live longer, but usually die before their 20s or 30s.
Serious
This is the default category. Conditions will likely end up in this category unless the condition appears to have a better fit to one
of the categories below. If there is variation in phenotype, the majority (>50%) have the most severe form.
Moderate/Mild
Signs and symptoms of the condition are typically not life threatening, although in rare instances they might be life threatening.
Patients with the condition typically experience only mild or moderate disruption to normal activities and functions (e.g., poor
vision vs. blindness). If there is treatment available, the treatment itself is not considered highly burdensome in terms of the
medical interventions or lifestyle modifications that are required. With treatment, patients may experience few or no symptoms
of the condition.
Unpredictable
There is a wide range in severity of phenotype. Factors that may vary include age at onset, severity of symptoms, or presence of
symptoms. It is not possible to tell how severe the condition will be for a particular individual based on genotype. For instance,
there may be families in which siblings carry the exact same mutations, but have vastly different expression of the phenotype.
The majority (>50%) will not have the most severe form.
Late Onset
Symptoms do not appear for most people (e.g., ~75–80%) until after age 20.
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